13F-HR filed by Lynx1 Capital Management LP
Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-04, with 23 holding rows worth $632,718,355.
- Accession
- 0001910456-26-000002
- Filer
- CIK 1910456
- Filed
- 2026-05-04
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2026
A holdings report, 23 entries on the cover page, a total value of $632,718,355 stated on the cover page (in dollars after the unit check, H1), rows summing to $632,718,355 with VALUE read as dollars as filed, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerLynx1 Capital Advisors LLC028-22145
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| STOKE THERAPEUTICS INC | 86150R107 | COM | 4,763,673 | $155,105,193 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 10,763,288 | $151,331,829 | dollars as filed | |
| CULLINAN THERAPEUTICS INC | 230031106 | COM | 8,963,500 | $127,371,335 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 2,611,568 | $88,349,345 | dollars as filed | |
| DENALI THERAPEUTICS INC COM | 24823R105 | Stock | 1,880,303 | $36,101,818 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 6,998,902 | $18,407,112 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 1,538,296 | $17,413,511 | dollars as filed | |
| Tscan Therapeutics Inc | 89854M101 | COM | 8,019,148 | $8,099,339 | dollars as filed | |
| XENCOR INC | 98401F105 | COMMON STOCK | 536,398 | $6,468,960 | dollars as filed | |
| PRECISION BIOSCIENCES INC | 74019P207 | COM NEW | 985,113 | $5,418,122 | dollars as filed | |
| PASSAGE BIO INC | 702712209 | COM NEW | 623,704 | $4,896,076 | dollars as filed | |
| NEUPHORIA THERAPEUTICS INC | 64136E102 | COM | 875,328 | $3,562,585 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 211,689 | $2,671,515 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 31,591 | $2,138,079 | dollars as filed | |
| IMMATICS N.V | N44445109 | SHS | 216,973 | $2,135,014 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 119,516 | $1,271,650 | dollars as filed | |
| VYNE THERAPEUTICS INC | 92941V308 | COM | 1,628,700 | $973,148 | dollars as filed | |
| WEREWOLF THERAPEUTICS INC | 95075A107 | CMN | 657,786 | $547,673 | dollars as filed | |
| IBIO INC | 451033708 | CMN | 68,076 | $129,344 | dollars as filed | |
| BOLT BIOTHERAPEUTICS INC | 097702203 | COM NEW | 30,800 | $124,432 | dollars as filed | |
| PROQR THERAPEUTICS NV | N71542109 | SHS EURO | 68,486 | $110,947 | dollars as filed | |
| ABSCI CORPORATION | 00091E109 | COM | 21,245 | $63,735 | dollars as filed | |
| TRAWS PHARMA INC | 68232V884 | COM NEW | 15,078 | $27,593 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001910456-26-000002 | this filing | 2026-05-04 | acceptance time not in the bulk data set |